BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Guerbet (GBT) - Another Proof That There Is No Difference Between Low-Osmolarity Contrast Agents And Iso-Osmolar Agent For Prevention Of Contrast-Induced Nephropathy


10/27/2006 2:38:29 PM

WASHINGTON, October 27 /PRNewswire/ -- Results from a recent clinical trial demonstrated that contrast agents Hexabrix(R) (Ioxaglate) and Visipaque(R) (Iodixanol) were no different in regard to nephrotoxicity in patients with chronic renal failure undergoing interventional procedures. Results from this clinical trial were presented at the Transcatheter Cardiovascular Therapeutics 18th Annual Scientific Symposium in Washington, D.C.

Principal Investigator Roxana Mehran, MD, of Columbia University (NY), who presented the results of the ICON clinical study [Ionic versus non-ionic Contrast to Obviate worsening Nephropathy after angioplasty in chronic renal failure patients] concluded that "There was no difference between the 2 products at any time with regards to the incidence of contrast induced nephropathy. In patients with chronic renal insufficiency, preventative measures, such as proper hydration and contrast volume optimization, remain key in reducing the risk."

The clinical study was a multi-center, double-blind, randomized pilot study designed to compare Ioxaglate, an ionic low-osmolar contrast media manufactured by Guerbet, and Iodixanol, a nonionic contrast agent. The study included 145 patients with stable chronic renal disease, particularly susceptible to developing a contrast induced nephropathy, with high rates of diabetes (46 %), hypertension (82 %) and congestive heart failure (26 %). They were randomized to receive either Ioxaglate (74 patients) or Iodixanol (71 patients) during their procedures. The two groups had similar baseline demographics, received similar contrast agent doses and were treated with similar procedures and adjunctive medications. Before and after contrast administration, all subjects were well hydrated with 0.45 normal saline and received approximately 3.7L of fluid.

The diagnosis of nephropathy induced by the injection of contrast agents is based on a creatinine increase of 0.5 mg/dL or by 25 % from baseline. The study's primary endpoint was the mean peak increase in creatinine between the administration of the contrast agent and the 3rd day following administration. The results showed that there was no statistically significant differences between the two treatment groups in regard to the increase in serum creatinine after coronary catheterization. These results confirm numerous other recent studies and meta-analyses which have shown no difference among various contrast media agents.

This study also supports the conclusion that the keys to managing the incidence of contrast-induced nephropathy include proper identification of at-risk patients, adequate hydration pre- and post-administration of the contrast medium, and optimization of the amount of contrast media administered to the patient.

About Hexabrix(R) (ioxaglate)

Hexabrix(R) is a low osmolality iodinated contrast agent whose unique anticoagulant and anti-platelet properties make it particularly suitable for interventional cardiology[1]. The benefits it brings during interventional surgical procedures were confirmed by a study in more than 500 patients[2] and published in 2006. Hexabrix(R), a registered trademark of Guerbet, has a broad range of indications in adults and children and is licensed in more than 60 countries[3].

About Guerbet

Guerbet (www.guerbet.com) is the only pharmaceutical group fully dedicated to medical imaging. It has the most comprehensive range of x-ray and MRI contrast media available worldwide. These products assist medical professionals (radiologists, cardiologists, oncologists, etc.) in better diagnosing and treating their patients (cardiovascular, cancer, inflammatory and degenerative diseases).

To develop new products and assure its future growth every year, Guerbet devotes significant resources to research and development: 160 R&D employees and approximately 10% of sales.

Guerbet is solidly positioned in Europe with a growing market share of already 25% and is expanding its presence in the United States and Japan.

[1] AL DIERI et al. 2003, HEPTINSTALL et al. 1998

[2] LE FEUVRE C. et al - Cathet Cardiovasc Interv 2006

[3] Please refer to the local Summary of product specifications for further details.

Media Contact : Mai Tran - Ruder Finn +33-(0)1-56-81-15-03, mtran@ruderfinn.fr

Guerbet

CONTACT: Media Contact : Mai Tran - Ruder Finn +33-(0)1-56-81-15-03,mtran@ruderfinn.fr



Read at BioSpace.com

Guerbet
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES